Optical counting relies on seeing each unit clearly. Our bottle line counts by mass using electromagnetic field detection, so transparent capsules or unusual tablet shapes don't affect accuracy. The count stays accurate regardless of what the product looks like.

If stability data or a new market requires a change, we can move between PVC/PVDC, Aclar and Alu/Alu without redesigning the pack from scratch. A material decision made at launch can still be revisited later in the product's life.

We product for both clinical trials and commercial supply, so a product can move from trial batches to full commercial volumes without transferring elsewhere partway through. A product can scale up without ever having to change site.

We've handled highly potent and controlled substances since our early years in Brighton. And that experience how shapes how we set up containment for new products. That history is what shapes how a new high-potency project gets set up today, not a standing start.

Batches involving scheduled substances are planned with the required security and access controls built into the schedule from the start, rather than adjusted around it. That planning is what keeps controlled drug batches on the same production schedule as everything else on site

Film coating isn't only there to finish a tablet. We apply coatings that support swallowing or mask taste, factors that matter for products taken regularly over time. The coating is chosen to match how the patient will actually take the dose, not applied as a standard step.

We manufacture specials and veterinary medicinal products alongside controlled drugs and hormonal products, each carrying its own regulatory and handling requirements. A less typical product gets the same oversight as everything else we manufacture.

Not every formulation follows a standard process. That groundwork is what lets a novel formulation move into commercial manufacture without being forced into a standard process.

Certification for 1 market doesn't always cover another. We're certified in the UK & Europe, so our facility already meets the requirements for both rather than working towards them separately. A product manufactured here can supply both markets without a 2nd approval process.

QP is a named, qualified individual who personally certifies each batch. They review full record, testing, any deviations. Keeping manufacture, testing & certification together gives the full picture to work from. Only when the QP is satisfied does the batch reach the market.

Routine release testing runs alongside manufacturing & packaging, but the bigger advantage is when something needs follow up. Samples, batch records & people who ran the process are all in one place and not across sites. Investigations are kept short and the supply keeps moving

Where cartoning, coding & pack configuration come together and the same tablet can be packed differently for different markets. Our cartoners run into serialisation equipment, so detail and unique identifier are applied in one pass. It lets one product serve several markets.

Blisters suit unit-dose presentation, tamper evidence & dose-by-dose traceability, whereas bottles suit higher counts & the markets that expect them. We run both so the format can follow what the product needs. Either way, the product reaches market in the pack that suits it.

For the most moisture, or oxygen-sensitive products, the blister choice usually comes down to Alu/Alu. We offer PVC/PVDC, Aclar and Alu/Alu, with the latter providing the strongest barrier of the three. Where a product needs it, Alu/Alu is the format that protects shelf life.

Every pack we serialise carries a unique identifier. We run in-line high-speed serialisation on blister and bottle lines to meet EU FMD, managing the data behind each code as closely as the printing. The outcome is traceability that holds from our line into the supply chain

High-potency products are made inside contained areas, sealed off. This protects operators from exposure and the production line itself. Cleaning validation is part of the discipline, not a separate exercise. Keeping compound off the operator and clear of the next run.

The MHRA governs how the product is made; the Home Office governs the substance itself. We hold Home Office license and run both sets of requirements together as part of normal production. It lets us treat controlled drug manufacture as a routine process.

We coat for cosmetic and performance reasons; the result depends on controlling the process. The spray rate, temperature and weight gain all matter to build the film evenly, this makes the release behave as intended. Control makes the coat reliable across the batch.

We fill two separate components into one hard gelatin capsule, keeping incompatible actives apart while delivering them in a single dose. On MG2 equipment, both fills stay within weight across the batch. It's a practical route to a combination product in a single dose.

Wet granulation involves bringing a blend together with liquid and then drying it back down before tableting. Getting the drying right means we get a granule that behaves predictably on the press.